Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network
Jakob Rudzki, Philipp Wohlfarth(Medical University of Vienna), Christina Peters(Cancer Research Institute of the Slovak Academy of Sciences), Andreas Petzer(Ordensklinikum Linz Barmherzige Schwestern), Dominik Wolf(Universität Innsbruck), Michael Leisch(Paracelsus Medical University), Peter Schlenke(Medical University of Graz), Richard Greil(Paracelsus Medical University), Clemens A. Schmitt(Kepler Universitätsklinikum), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Wolfgang Holter, Michael Girschikofsky(Krankenhaus der Elisabethinen), Andishe Attarbaschi(Cancer Research Institute of the Slovak Academy of Sciences), Peter Neumeister(Medical University of Graz), Hildegard Greinix(Medical University of Graz), Wolfgang Schwinger(Medical University of Graz), Ulrich Jaeger(Medical University of Vienna), Nina Worel(Medical University of Vienna)
Cited by 1
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Senescence and cancer — role and therapeutic opportunities
|Nature Reviews Clinical Oncology|2022|727
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540